Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 14/20 | 0.60 |
| ▸ | PLK4 | O00444 | 11/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974392 | 0.84 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1976316 | 0.84 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1970402 | 0.84 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1975208 | 0.84 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1972573 | 0.84 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1972624 | 0.81 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1973511 | 0.81 | AURKB (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1974120 | 0.81 | PLK4 (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1973346 | 0.81 | PLK4 (0.57) | AURKBPLK4FLT3CYP2C19GSK3B | |
| SCHEMBL1973178 | 0.76 | GSK3B (0.60) | AURKBPLK4FLT3CYP2C19GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8354443-B2 | Cyclopropane indolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144106-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | AURKB 3942/4885PLK4 1385/4885FLT3 4115/4885 |
| US-20130102604-A1 | NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES | GPR119, CPT1A, IRS1 | AURKB 3954/4885PLK4 1323/4885FLT3 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.